nach oben

Erschienen in:

01.11.2010 | Original paper

The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study

verfasst von: Mari-Anne Rowlands, Jeff M. P. Holly, David Gunnell, Rebecca Gilbert, Jenny Donovan, J. Athene Lane, Gemma Marsden, Simon M. Collin, Freddie Hamdy, David E. Neal, Richard M. Martin

Erschienen in: Cancer Causes & Control | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

Adiposity is positively associated with advanced, metastatic, and fatal prostate cancer. Obesity-related variations in insulin-like growth factors (IGF-I and -II) and their binding proteins (IGFBPs) could underlie these associations.

Methods

We investigated associations of adiposity throughout the life course (determined retrospectively) with serum levels of IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in a population-based study of 1,106 healthy men.

Results

IGF-I and IGF-II showed inverted U-shaped associations with adult body mass index (BMI) (p quadratic model = 0.04 and 0.06, respectively), although differences between quartiles with the highest and lowest IGF-I levels were small (no more than 5 ng/ml). IGFBP-2 was strongly inversely related to adult BMI (−22% change per SD increase in BMI; 95% confidence interval (CI) −24% to −19%) and waist circumference (−18% change per SD increase in waist circumference; 95% CI −20% to −15%) (p < 0.001). IGFBP-3 was positively related to BMI (63.5 ng/ml increase per SD increase in BMI; 95% CI −2.69 to 129.8, p = 0.06). IGFBP-2 and IGFBP-3 were strongly related to body shape change from childhood to adulthood, with men who gained the most weight having the lowest IGFBP-2 (9% lower per category body shape change; 95% CI −11% to −7%, p < 0.001) and the highest IGFBP-3 (50 ng/ml increase per category; 95% CI 8 to 92, p = 0.02).

Conclusions

We provide evidence that adiposity and change in body shape through the life course are related to the IGF system, with the largest effect of adiposity being to lower IGFBP-2, a possible marker of insulin resistance. The results suggest that circulating IGF-I levels may not be important mediators of the association of adiposity with aggressive prostate cancer, but the role of IGFBP-2 deserves further investigation.

Nur mit Berechtigung zugänglich

Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global Cancer Statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRef

Baade PD, Coory MD, Aitken JF (2004) International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control 15:237–241CrossRefPubMed

World Cancer Research Fund: Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective (2008) 2 edn

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578CrossRefPubMed

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591CrossRefPubMed

Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R (2009) Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev 18(3):808–815CrossRefPubMed

MacInnis R, English D (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17(8):989–1003CrossRefPubMed

Wright ME, Chang S-C, Schatzkin A et al (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109:675–684CrossRefPubMed

Gong ZH, Neuhouser ML, Goodman PJ et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15(10):1977–1983CrossRefPubMed

10.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638CrossRefPubMed

11.

Andersson SO, Wolk A, Bergstrom R et al (1997) Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 89(5):385–389CrossRefPubMed

12.

Snowdon DA, Phillips RL, Choi WARR (1984) Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 120(2):244–250PubMed

13.

Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1997) Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 6(8):557–563PubMed

14.

Efstathiou JA, Bae K, Shipley WU et al (2007) Obesity and mortality in men with locally advanced prostate cancer. Cancer 110:2691–2699CrossRefPubMed

15.

Rodriguez C, Freedland SJ, Deka A et al (2007) Body mass index, weight change, and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 16(1):63–69CrossRefPubMed

16.

Ma J, Li H, Giovannucci E et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047CrossRefPubMed

17.

Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132:2208–2225CrossRefPubMed

18.

Lukanova A, Soderberg S, Stattin P et al (2002) Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes Control 13(6):509–516CrossRefPubMed

19.

Martin RM, Holly JMP, Davey Smith G, Gunnell D (2006) Associations of adiposity from childhood into adulthood with insulin resistance and the insulin-like growth factor system: 65 year follow-up of the Boyd Orr Cohort. J Clin Endocrinol Metab 91:3287–3295CrossRefPubMed

20.

Ben-Shlomo Y, Holly J, McCarthy A et al (2003) An investigation of fetal, postnatal and childhood growth with insulin-like growth factor I and binding protein 3 in adulthood. Clin Endocrinol 59(3):366–373CrossRef

21.

Kajantie E, Fall CHD, Seppala M et al (2003) Serum insulin-like growth factor (IGF)-I and IGF-binding protein-1 in elderly people: relationships with cardiovascular risk factors, body composition, size at birth, and childhood growth. J Clin Endocrinol Metab 88(3):1059–1065CrossRefPubMed

22.

Gapstur SM, Kopp P, Chiu BCH, Gann PH, Colangelo LA, Liu K (2004) Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-I and IGF binding protein-3 levels in black and white men: the CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 13(12):2208–2216PubMed

23.

Chang S, Wu XF, Yu H, Spitz MR (2002) Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiol Biomarkers Prev 11(8):758–766PubMed

24.

Benbassat CA, Maki KC, Unterman TG (1997) Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J Clin Endocrinol Metab 82(5):1484–1491CrossRefPubMed

25.

Gunnell D, Oliver SE, Donovan JL et al (2004) Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? J Clin Endocrinol Metab 89(1):213–218CrossRefPubMed

26.

Roddam AW, Allen NE, Appleby P et al (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149(7):461–471PubMed

27.

Rowlands M, Gunnell D, Harris R, Vatten LJ, Holly JMP, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429CrossRefPubMed

28.

Oliver SE, Gunnell D, Donovan J et al (2004) Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 108:887–892CrossRefPubMed

29.

Schneider HJ, Saller B, Klotsche J et al (2006) Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. EUR 154(5):699–706

30.

Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK, Key TJ (2003) Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control 14:65–74CrossRefPubMed

31.

Bezemer ID, Rinaldi S, Dossus L et al (2005) C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 16(5):561–572CrossRefPubMed

32.

Gram IT, Norat T, Rinaldi S et al (2006) Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes 30(11):1623–1631CrossRef

33.

Fowke J, Matthews C, Yu H et al. (2009) Racial differences in the association between body mass index (BMI) and serum IGF-1, IGF-2, and IGFBP-3. Endocr Relat Cancer: ERC-09

34.

Sandhu MS, Gibson JM, Heald AH, Dunger DB, Wareham NJ (2003) Low circulating IGF-II concentrations predict weight gain and obesity in humans. Diabetes 52(6):1403–1408CrossRefPubMed

35.

van den Beld AW, Blum WF, Pols HA, Grobbee DE, Lamberts SW (2003) Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. Eur J Endocrinol 148(6):627–634CrossRefPubMed

36.

MacInnis R, English D (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17(8):989–1003CrossRefPubMed

37.

Kristal AR, Gong Z (2007) Obesity and prostate cancer mortality. Future Oncol 3(5):557–567CrossRefPubMed

38.

Albanes D, Weinstein SJ, Wright ME et al (2009) Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 101(18):1272–1279CrossRefPubMed

39.

Hernandez BY, Park SY, Wilkens LR, Henderson BE, Kolonel LN (2009) Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 18(9):2413–2421CrossRefPubMed

40.

41.

Zuccolo L, Harris R, Gunnell D et al (2008) Height and prostate cancer risk: a large nested case-control study (protect) and meta-analysis. Cancer Epidemiol Biomarkers Prev 17(9):2325–2336CrossRefPubMed

42.

Stunkard AJ, Sorensen T, Schulsinger F (1983) Use of a Danish adoption register for the study of obesity and thinness. The genetics of neurological and psychiatric disorders. Raven Press, New York, pp 115–120

43.

Bulik CM, Wade TD, Heath AC, Martin NG, Stunkard AJ, Eaves LJ (2001) Relating body mass index to figural stimuli: population-based normative data for Caucasians. Int J Obes 25:1517–1524CrossRef

44.

Expert Panel on Identification EaToOaOiA (1998) Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 158(17):1855–1867CrossRef

45.

Tricoli JV, Winter DL, Hanlon AL et al (1999) Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 54(1):178–182CrossRefPubMed

46.

Cruickshank JK, Heald AH, Anderson S et al (2001) Epidemiology of the insulin-like growth factor system in three ethnic groups. Am J Epidemiol 154(6):504–513CrossRefPubMed

47.

Landin-Wilhelmsen K, Wilhelmsen L, Lappast G et al (1994) Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 41(3):351–357CrossRef

48.

Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D (2004) The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the rancho bernardo study. J Clin Endocrinol Metab 89(1):114–120CrossRefPubMed

49.

DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le ML (2004) Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 13(9):1444–1451PubMed

50.

O’Connor KG, Tobin JD, Harman SM et al (1998) Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men. J Gerontol A Biol Sci Med Sci 53A(3):M176–M182

51.

Langlois JA, Rosen CJ, Visser M et al (1998) Association between insulin-like growth factor i and bone mineral density in older women and men: the Framingham heart study. J Clin Endocrinol Metab 83(12):4257–4262CrossRefPubMed

52.

Mucci LA, Tamimi R, Lagiou P et al (2001) Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 87(9):814–820CrossRefPubMed

53.

Probst-Hensch NM, Wang H, Goh VHH, Seow A, Lee H-P, Yu MC (2003) Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. Cancer Epidemiol Biomarkers Prev 12(8):739–746PubMed

54.

Tricoli JV, Winter DL, Hanlon AL et al (1999) Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 54(1):178–182CrossRefPubMed

55.

Holly J, Perks C (2006) The role of insulin-like growth factor binding proteins. Neuroendocrinology 83:154–160CrossRefPubMed

56.

Shariat SF, Lamb DJ, Kattan MW et al (2002) Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20(3):833–841CrossRefPubMed

57.

Perks C, Vernon EG, Rosendahl AH, Tonge D, Holly JMP (2007) IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 26:5966–5972CrossRefPubMed

58.

Thissen J-P, Ketelslegers J-M, Underwood LE (1994) Nutritional regulation of the insulin-like growth factors. Endocr Rev 15(1):80–101PubMed

59.

Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92(18):1472–1489CrossRefPubMed

60.

Garcia-Galiano D, Sanchez-Garrido MA, Espejo I et al (2007) IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 17(4):493–503CrossRefPubMed

61.

Inman BA, Harel F, Audet JF et al (2005) Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol 47(5):695–702CrossRefPubMed

62.

Mehrian-Shai R, Chen CD, Shi T et al (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3 K/Akt pathway activation in glioblastoma and prostate cancer. Proc Nat Acad Sci 104(13):5563–5568CrossRefPubMed

63.

Bubendorf L, Kolmer M, Kononen J et al (1999) Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91(20):1758–1764CrossRefPubMed

64.

Degraff DJ, Aguiar AA, Sikes RA (2009) Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 1(2):115–130PubMed

65.

Rose D, O’Reilly K (1998) The ESRC review of government social classifications. Office for national statistics & economic and social research council

Titel: The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study
verfasst von: Mari-Anne Rowlands
Jeff M. P. Holly
David Gunnell
Rebecca Gilbert
Jenny Donovan
J. Athene Lane
Gemma Marsden
Simon M. Collin
Freddie Hamdy
David E. Neal
Richard M. Martin
Publikationsdatum: 01.11.2010
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 11/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9610-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study